Skip to content

Study · Not a test of the peptide alone · 2003

3 results

Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide inhibit feeding in the chick brain by different mechanisms.

Tachibana T, Tomonaga S, Oikawa D, Saito S, Takagi T, Saito ES, Boswell T, Boswell T, Furuse M

Neuroscience letters1 Sept 2003Cited by 29 (Europe PMC)

PMID12893417 (opens in a new tab)DOI10.1016/s0304-3940(03)00646-3 (opens in a new tab)PepBankPUB-12893417
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In chicks, the PAC1 antagonist PACAP (6-38) did not attenuate the anorexigenic effect of VIP.

    In plain wordsIn chicks, a PAC1 receptor blocker did not reduce the appetite-lowering effect of VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP anorexic effect with PAC1 antagonist
    Study

    chickn: not reported in source

    in vivo
    Comparator
    VIP alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    ICV co-injection of PACAP (6-38), a PAC1 receptor antagonist, attenuated the anorexigenic effect of PACAP but not VIP.
    1 context sentence
    Summary · context
    We investigated which receptor mediates the anorexigenic effects of these peptides in chicks.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In chicks, the VPAC receptor antagonist did not affect the anorexigenic effect of VIP.

    In plain wordsIn chicks, a VPAC receptor blocker did not change the appetite-lowering effect of VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP anorexic effect with VPAC antagonist
    Study

    chickn: not reported in source

    in vivo
    Comparator
    VIP alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    On the other hand, ICV co-injection of [D-p-Cl-Phe6, Leu17]-VIP, a VPAC receptor antagonist, did not affect the effects of both peptides.
    1 context sentence
    Summary · context
    We investigated which receptor mediates the anorexigenic effects of these peptides in chicks.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In chicks, intracerebroventricular anti-chicken VIP antiserum stimulated feeding.

    In plain wordsIn chicks, blocking the body's own VIP with an antiserum raised feeding.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseFeeding after anti-chicken VIP antiserum
    Study

    chickn: not reported in source

    in vivo
    Comparator
    Control
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    a subsequent experiment demonstrated that ICV injection of anti-chicken VIP antiserum stimulated feeding
    1 context sentence
    Summary · context
    We investigated which receptor mediates the anorexigenic effects of these peptides in chicks.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.